Blocking S194 phosphorylation suppresses NLRP3 inflammasome activation in cryopyrin-associated periodic syndrome (CAPS) patients, suggesting its importance as a therapeutic target for treating NLRP3-related diseases [143]. Here, NLRP3 is linked to cryopyrin-associated periodic syndrome.